2.01
price up icon1.26%   0.025
after-market Dopo l'orario di chiusura: 2.03 0.02 +1.00%
loading
Precedente Chiudi:
$1.985
Aprire:
$2.01
Volume 24 ore:
191.88K
Relative Volume:
1.76
Capitalizzazione di mercato:
$20.05M
Reddito:
-
Utile/perdita netta:
$-34.77M
Rapporto P/E:
-0.6073
EPS:
-3.3097
Flusso di cassa netto:
$-29.79M
1 W Prestazione:
-22.24%
1M Prestazione:
-57.95%
6M Prestazione:
-80.97%
1 anno Prestazione:
-83.32%
Intervallo 1D:
Value
$1.95
$2.025
Intervallo di 1 settimana:
Value
$1.95
$2.70
Portata 52W:
Value
$1.95
$19.35

Atossa Therapeutics Inc Stock (ATOS) Company Profile

Name
Nome
Atossa Therapeutics Inc
Name
Telefono
206.588.0256
Name
Indirizzo
1448 NW MARKET STREET, SEATTLE, WA
Name
Dipendente
14
Name
Cinguettio
@atossainc
Name
Prossima data di guadagno
2026-08-11
Name
Ultimi documenti SEC
Name
ATOS's Discussions on Twitter

Compare ATOS vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
ATOS icon
ATOS
Atossa Therapeutics Inc
2.01 20.05M 0 -34.77M -29.79M -3.3097
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
451.63 114.63B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
609.94 63.95B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
877.72 54.58B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
278.09 37.13B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
162.99 34.65B 742.00K -1.37B -1.07B -7.0731

Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2018-01-26 Iniziato Maxim Group Buy

Atossa Therapeutics Inc Borsa (ATOS) Ultime notizie

pulisher
Jun 18, 2026

Atossa Therapeutics Inc (ATOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

Atossa Therapeutics Inc (ATOS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

Atossa Therapeutics Inc (ATOS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 18, 2026
pulisher
Jun 17, 2026

Atossa Therapeutics Inc (ATOS) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Atossa Therapeutics Inc (ATOS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Atossa Therapeutics Inc (ATOS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Atossa Therapeutics Inc (ATOS) Institutional Confidence - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Atossa Therapeutics Inc (ATOS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jun 17, 2026
pulisher
Jun 15, 2026

Atossa Therapeutics brings medical innovation to Hudson Institute strategic discussions - Traders Union

Jun 15, 2026
pulisher
Jun 15, 2026

Atossa Therapeutics Inc (ATOS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jun 15, 2026
pulisher
Jun 13, 2026

Atossa Therapeutics (ATOS) Q1 2026 Earnings: Narrowing Losses with Positive EPS SurpriseRevenue Warning Signal - newsline.com

Jun 13, 2026
pulisher
Jun 13, 2026

Atossa Therapeutics closes $4.5M registered direct offering By Investing.com - Investing.com Australia

Jun 13, 2026
pulisher
Jun 12, 2026

Atossa Therapeutics closes $4.5M registered direct offering - Investing.com

Jun 12, 2026
pulisher
Jun 12, 2026

Cancer-drug developer Atossa raises $4.5M, eyes $12M more - Stock Titan

Jun 12, 2026
pulisher
Jun 12, 2026

Atossa Therapeutics Announces Up To $16.5 Million Registered Direct Offering - Pulse 2.0

Jun 12, 2026
pulisher
Jun 12, 2026

Atossa Therapeutics examines biosecurity and scientific innovation after COVID 19 lessons - Traders Union

Jun 12, 2026
pulisher
Jun 12, 2026

Atossa Therapeutics (NASDAQ: ATOS) sells 1.36M shares with warrants in $4.5M deal - Stock Titan

Jun 12, 2026
pulisher
Jun 12, 2026

Atossa Therapeutics prices up to $16.5M direct offering - MSN

Jun 12, 2026
pulisher
Jun 11, 2026

Market Movers | Winners: XXII, PPCB, CCHH | Losers: BCPC, ATOS, BATL - Trefis

Jun 11, 2026
pulisher
Jun 11, 2026

Atossa Therapeutics, Inc. (ATOS) Latest Stock News & Headlines - Yahoo Finance

Jun 11, 2026
pulisher
Jun 11, 2026

Top Midday Decliners - Moomoo

Jun 11, 2026
pulisher
Jun 11, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

Jun 11, 2026
pulisher
Jun 11, 2026

Crude Oil Edges Higher; Driven Brands Posts Upbeat Earnings - Benzinga

Jun 11, 2026
pulisher
Jun 11, 2026

Dow Jumps Over 250 Points; US Initial Jobless Claims RiseAtossa Therapeutics (NASDAQ:ATOS), Big Tree C - Benzinga

Jun 11, 2026
pulisher
Jun 11, 2026

Atossa Therapeutics Launches $16.5 Million Registered Direct Offering - marketscreener.com

Jun 11, 2026
pulisher
Jun 11, 2026

Atossa Therapeutics stock tumbles on $4.5M stock offering - Investing.com UK

Jun 11, 2026
pulisher
Jun 11, 2026

Atossa Therapeutics Announces Registered Direct Offering and Warrants - TipRanks

Jun 11, 2026
pulisher
Jun 11, 2026

Atossa Therapeutics stock tumbles on $4.5M stock offering By Investing.com - Investing.com Nigeria

Jun 11, 2026
pulisher
Jun 11, 2026

Atossa Therapeutics raises $4.5M in registered direct offering - Investing.com

Jun 11, 2026
pulisher
Jun 11, 2026

Atossa Therapeutics raises $4.5M in registered direct offering By Investing.com - Investing.com Australia

Jun 11, 2026
pulisher
Jun 11, 2026

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Jun 11, 2026
pulisher
Jun 11, 2026

Atossa Therapeutics Prices Registered Direct Offering at $3.30, Netting About $4.1 Million - TradingView

Jun 11, 2026
pulisher
Jun 11, 2026

Atossa Therapeutics (ATOS) prices $3.30 registered direct stock and warrant sale - Stock Titan

Jun 11, 2026
pulisher
Jun 11, 2026

Biotech Atossa targets up to $16.5M to fund clinical work - Stock Titan

Jun 11, 2026
pulisher
Jun 10, 2026

ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug - Stocktwits

Jun 10, 2026
pulisher
Jun 10, 2026

Atossa Therapeutics highlights Endoxifen progress as potential Breast Cancer treatment - Proactive financial news

Jun 10, 2026
pulisher
Jun 08, 2026

Atossa Therapeutics (ATOS) Climbs 1.79% as Shares Approach Key Resistance at $4.78Wedge Breakout - newsline.com

Jun 08, 2026
pulisher
Jun 08, 2026

Lowering mammographic breast density could cut future cancer risk, ATOSSA THERAPEUTICS, INC. asserts - Traders Union

Jun 08, 2026
pulisher
Jun 01, 2026

CEO Chat with Steven Quay, MD, PhD, Chairman, President, & CEO of Atossa Therapeutics - Yahoo Finance

Jun 01, 2026
pulisher
May 29, 2026

Atossa Therapeutics (ATOS) Edges Higher on Modest Gains, Holds Above Key SupportReversal Trade - The Legal Advocate

May 29, 2026
pulisher
May 29, 2026

ATOS News | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill

May 29, 2026
pulisher
May 29, 2026

Cash from investing activities of Atossa Therapeutics, Inc. – DUS:YAG - TradingView

May 29, 2026
pulisher
May 27, 2026

Atossa Therapeutics (ATOS) Highlights Promising Data for (Z)-End - GuruFocus

May 27, 2026
pulisher
May 27, 2026

Atossa presents preclinical data on breast cancer drug at ASCO - Investing.com UK

May 27, 2026
pulisher
May 27, 2026

Atossa Presents New Data Highlighting (Z)-Endoxifen's Potential in Breast Cancer - Intellectia AI

May 27, 2026
pulisher
May 27, 2026

Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial - PR Newswire

May 27, 2026
pulisher
May 26, 2026

Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.

May 26, 2026
pulisher
May 26, 2026

ATOS Stock Price, Quote & Chart | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill

May 26, 2026
pulisher
May 23, 2026

Atossa Therapeutics (ATOS) Holds Steady Near Support Amid Modest DeclineScalping Stock Signals - newsline.com

May 23, 2026
pulisher
May 21, 2026

Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy - BioSpace

May 21, 2026
pulisher
May 20, 2026

Atossa Therapeutics advances research on Z-endoxifen for Duchenne muscular dystrophy - Traders Union

May 20, 2026

Atossa Therapeutics Inc Azioni (ATOS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$31.43
price up icon 0.74%
$90.89
price down icon 1.44%
$52.96
price down icon 1.38%
$63.96
price up icon 3.50%
ONC ONC
$270.15
price up icon 2.84%
$162.99
price up icon 3.31%
Capitalizzazione:     |  Volume (24 ore):